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Abstract
Background: To examine the contemporary role of ureteroscopy in the diagnosis of upper urinary tract urothelial
carcinoma.
Methods: We retrospectively evaluated 116 diagnostic ureteroscopies, performed in our institution to rule out
primary UTUC. Demographics, cytological findings and interpretation of preoperative imaging were obtained.
Ureteroscopic diagnosis and histological results were recorded and the predictive values of diagnostic studies were
determined. Follow-up data was reviewed to evaluate the oncological outcomes in patients treated endoscopically.
Results: The pre-ureteroscopic evaluation included CTU in 91 (78 %) patients. Positive and Negative predictive
values of CTU were 76 and 80 %, respectively. Typical filling defect on CTU was demonstrated in 38 of 89 patients.
UTUC has been ruled out in 9 patients (24 %) with suspicious filling defect on CTU. Endoscopic approach was
implemented in 7 patients (18 %). During a median follow up period of 17 months (IQR, 9–25) none of the
followed patients experienced disease progression.
Conclusions: Nephroureterectomy was spared from 42 % of patients who underwent diagnostic ureteroscopy for
suspected UTUC, demonstrated on CTU. In about half of those patients tumor has been ruled out and the others
were managed endoscopically. Therefore, diagnostic ureteroscopy is advised as a crucial step in confirming UTUC
and treatment planning.
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Background
Upper urinary tract urothelial carcinoma (UTUC) is an
uncommon malignancy, accounting for ~5 % of urothe-
lial tumors [1]. The diagnosis of UTUC can be challen-
ging, requiring a combination of radiographic, cytologic
and endoscopic means. Time honored radiological tools
such as intravenous urography and retrograde uretropye-
lograpy are currently replaced by modern computerized
tomography urography (CTU) [2]. Diagnostic uretero-
scopy is often performed following CTU. Flexible uretero-
scopy allows exploration of the upper urinary tract and is
beneficial when diagnostic uncertainty exists. It has the
advantages of offering direct view of the tumor, ruling out
other pathologies and achieving tissue diagnosis. Although
nephrouereterectomy is considered the gold standard
treatment of UTUC, endoscopic ablation and resection of
the tumor can be successfully utilized in selected cases
based on tumor size and histology, as determined during
ureteroscopoy. In low grade low volume tumors endo-
scopic management provides cancer related and overall
survival equivalent to that of nephroureterectomy [3].
Despite the above, the routine use of ureterosocpy fol-
lowing CTU is controversial. Ureteroscopy is an inva-
sive procedure that may be associated with morbidity
as well as a potential risk of tumor seeding [4, 5]. In the
last edition of “Campbell’s urology” the authors do not
support a routine ureteroscopic confirmation of UTUC
[6], while the European guidelines on UTUC (2015 ver-
sion) advocate the use of diagnostic ureteroscopy with
biopsy, especially in cases where additional information
will impact treatment decisions. The purpose of this
study was to evaluate the diagnostic value of uretero-
scopy in patients who underwent workup for suspected
UTUC and to assess the impact of ureteroscopy on the
management of UTUC.
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Methods
This study was approved by “Rabin Medical Center”
ethics committee. Between 2003 and 2010, 1818 ureter-
oscopies, were performed at our institution, of which
116 (6.3 %) were diagnostic, aimed to rule out primary
UTUC. The indications for diagnostic ureteroscopy in-
cluded painless hematuria with positive urinary cytology
and negative cystoscopy or imaging findings that may in-
dicate UTUC. CTU was not performed in patients with
chronic renal failure (eGFR < 30 mL/min/1.73 m2) or
severe contrast allergy. Although ultrasound is not ac-
cepted as a standard modality for UTUC investigation,
we reported on ultrasound results when it was available
(either performed as first imaging modality in the com-
munity or in cases of chronic renal failure or severe
contrast allergy). The medical chart of each patient was
reviewed to obtain demographics, cytological findings
and the interpretation of preoperative imaging. Because
of the retrospective design of this study our institu-
tional ethics committee waived the need for written in-
formed consent from participants.
Complete endoscopic examination of the ureter, renal
pelvis and calyx has been performed in all patients. Ure-
teroscopy was performed following a retrograde study,
using 8FR rigid ureteroscope (Wolf ), advancing the in-
strument as much as possible. Renal inspection was per-
formed using flexible ureteroscope (DUR-8 (ACMI) or
in later years the Flex- X™ (Stortz)). Biopsy forceps or
stone collection basket were used to obtain tissue from
suspected lesion. Tumor grade and stage were assigned
using the world health organization classification [7] and
the 6th edition of the AJCC/UICC TNM staging system
[8] by specialized pathologists at our institution. Patients
with histologically confirmed UTUC were referred to
nephroureterectomy usually within one month following
the diagnostic procedure or, in selected cases, managed
conservatively with endoscopic resection. Patients with
low grade, <1 cm UTUC were eligible for endoscopic
treatment. Holmium laser and a bugbee electrode were
utilized for tumor resection and ablation.
Intra- and peri-operative complications were reviewed
and staged according to Clavien-Dindo classification [9].
The first follow-up ureteroscopy was preformed 3 month
after endoscopic tumor resection. Thereafter, patients
were followed with ureteroscopy or CTU, alternately,
every 3 months during the first two years. Patients with
chronic kidney disease were referred to a nephrologist
for consultation. Follow-up data was reviewed to include
the oncological outcomes (disease recurrence and pro-
gression) of patients managed with nephron sparing
endoscopic approach.
The diagnostic value (positive and negative predictive
values) of urine cytology, ultrasound and CTU was de-
termined. Positive cytology was defined as malignant
cells or atypical cells, highly suggestive of urothelial car-
cinoma. Intraluminal Soft-tissue mass, demonstrated by
ultrasound, or filling defect in contrast opacified collect-
ing system, demonstrated by CTU, were considered
positive for UTUC. The endoscopic appearance, sup-
ported by histologic examination, when available, served
as the standard of reference.
Results
Clinical characteristics and diagnostic studies
The study cohort included 116 patients who underwent
diagnostic ureteroscopy between November 2003 and
December 2010. Demographics and clinical characteris-
tics of the study patients are summarized in Table 1.
Half (51 %) of the patients reported at least one episode
of gross hematuria and 35 % had a history of lower
urinary tract urothelial carcinoma. The preuretero-
scopic evaluation included urine cytology, ultrasound
and CTU in 91 (78 %), 84 (72 %) and 89 (77 %)
patients, accordingly. Results of all three studies were
available in 47 patients (40.5 %). CTU was not per-
formed in 22 patients with chronic renal failure and 3
patients with severe contrast allergy. Detailed descrip-
tion of the findings, according to the performed study
is presented in Table 2. Visual diagnosis of UTUC was
made in 47 patients (40 %), supported by histology in
38 of them (80 %). A reliable histological report could
not be obtained in 9 patients due to insufficient amount
of tissue or technical artifacts.
Of the 38 patients, 27 (71 %) had low grade disease
and 11(29 %) had high grade disease on biopsy. In 24
cases tumor stage was determined. Ta, T1 and T2 were
Table 1 Demographic and clinical patient characteristics
Characteristic N = 116
Age, years
Median (IQR) 70.5
Mean (range) 68 (16–90)






History of LUTUC n, (%)
None 75 (65)
Low grade 24 (21)
High grade 17 (14)
LUTUC Lower urinary tract urothelial carcinoma
a Defined as three or more red blood cells per high power microscopic filed
on urinary sediment
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assigned in 21 (87 %), 2 (8 %) and 1 (5 %) cases,
respectively.
All complications observed in this study were Clavien
grade I or II. Intraoperative complications included con-
trast extravasation, observed during ureteroscopy, in 4
patients (3 %). All patients were managed with ureteral
stent for one week with no clinical sequel. Febrile UTI
and renal colic were observed after ureteroscopy in 7
(6 %) and 4 (3 %) patients, respectively. Conservative
treatment was successfully applied in all cases.
Correlation with ureteroscopy findings
Positive urinary cytology, reported in 36 of 91 patients,
included atypia in 26 and dysplasia in 10 patients. The
calculated PPV and NPV for UTUC were 47 and 58 %,
accordingly. Sonographic appearance of intraluminal
mass in 9 patients (9 %), yielded PPV and NPV of 89
and 65 %. Typical filling defect, demonstrated during
the excretory phase of CTU, was described in 38 of 89
patients. PPV and NPV of CTU were 76 and 80 %, re-
spectively. Considering “wall thickening” as a positive
result, increased the NPV to 90 % but decreased the
PPV to 67 %. In 4/39 patients with confirmed UTUC
no “filing defect” or “wall thickening” was demonstrated
on CTU. Three of these patients had Ta low grade tu-
mors in the ureter and one patient had carcinoma in
situ of the renal pelvis. Table 3 summarizes the associ-
ation between the results of preoperative studies and
ureteroscopic diagnosis.
Filling defect on CTU – ureteroscopic results and
therapeutic outcomes
UTUC had been confirmed during URS in 29 of 38
(76 %) patients with characteristic filling defect on CTU.
7 patients had high grade disease on biopsy, including:
stage T1 in 4, T2 in 1 and non- determined stage in 2
patients. 20 patients had Ta low grade and in 2 patients
neither stage nor grade could be determined. UTUC has
been ruled out in 9 patients (24 %). Mucosa fold, small
extraluminal mass and parapelvic hyperdense cyst and
bullous mucosal edema of the renal pelvis were found in
4 patients and no findings, explaining the filling defects,
were reported in the remaining 5 patients. No additional
intervention was required in these cases.
Patients with UTUC were subjected to nephroureter-
ectomy or endoscopic resection according to tumor
characteristics (see above). Two patients, found to have
metastatic disease, were referred to cisplatin based
chemotherapy.
Overall, 20 patients underwent nephroureterectomy
while nephron sparing endoscopic approach was imple-
mented in 7 patients who underwent tumor resection
with continues surveillance. One of these patients was
lost to follow-up. During a median follow up period of
17 months (IQR, 9–25) none of the 6 followed patients
experienced disease progression. Tumor recurrence was
diagnosed and treated successfully in 2 patients, 5 and
14 months after initial resection (Fig. 1).
Discussion
CTU is currently the recommended imaging modality
for evaluation of the upper urinary tract. With ongoing
radiological improvements, the added value of diagnos-
tic ureteroscopy is not always clear. We examined the
Table 2 Results of preoperative evaluation - cytological,
sonographic and radiographic findings
Method






Intra-luminal mass 9 (9)
Dilation 43 (37)
No finding 32 (27)
N/A 32 (27)
CTU (n, %)
Filling defect 38 (33)
Wall thickening 14 (12)
Dilation 39 (33)
External mass 5 (4)
No finding 12 (10)
N/A 27 (22)
Table 3 Correlation of preoperative studies with the
ureteroscopic results
Preoperative findings Ureteroscopic results
Positive for UTUC Negative for UTUC Total
CTU
Positive 29 9 38
Negative 10 41 51
Total 39 50 89
Ultrasound
Positive 8 1 9
Negative 26 49 75
Total 34 50 84
Urine cytology
Positive 17 19 36
Negative 23 32 55
Total 40 51 91
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current role of ureteroscopy in the diagnosis of urothe-
lial carcinoma. We found that nephroureterectomy was
spared from 42 % (16/38) of patients who underwent
ureteroscopy for presumptive UTUC, based on CTU.
UTUC was ruled out in 9 patients and treated endo-
scopically in 7 patients. In the nephron sparing group
we observed no disease progression during short term
follow-up.
Although UTUC is relatively rare, its incidence has
increased in the last decades [10, 11]. One possible ex-
planation for this trend is increased use of CTU, a sen-
sitive tool to detect upper urinary tract abnormalities
[2]. The ability of CTU to demonstrate small tumors is
well accepted but at the same time, growing use of
CTU may increase the detection of benign findings.
The positive predictive value (PPV) of CTU for the de-
tection of UTUC is variable, depends on CTU tech-
nique and has been reported to be moderate (50-80 %)
[12–15]. Intra- and extra-luminal conditions may simu-
late UTUC on CTU. Inflammatory changes, debris or
blood clots may mimic intraluminal tumor. Indentation
by extraluminal mass or vascular malformation may
also cause false positive results [12]. In our study, the
PPV of CTU was 80 %. Non-UTUC findings (mucosa
fold, small extraluminal mass and parapelvic hyper-
dense cyst and bullous mucosal edema) were found
during ureteroscopy in 4/9 cases and normal upper
urinary tract was described in 5/9 cases. None of these
patients had positive urinary cytology. Sadow et al. re-
ported on extremely low PPV in small (≤5 mm) upper
urinary tract filling defects on CTU [14]. All 17 cases of
small filling defects in their study were found to be
false positive. In accordance, the five completely normal
ureteroscopies in our study were performed in patients
with small filling defects on CTU.
The treatment options for confirmed UTUC include
nephroureterectomy or, in selected patients, nephron
sparing procedure. In the last two decades endoscopic
management of UTUC has been extended from pa-
tients with imperative indications (chronic kidney dis-
ease, bilateral disease or solitary kidney) to selected
patients with elective indications. In a review article,
Cutress et al. reported that the long term renal preser-
vation rate in patients treated endoscopically is 80 %
[16]. This information is highly important when consid-
ering the potential cardiovascular and overall survival
benefits of renal function preservation [17]. Recently
published, long term retrospective studies showed that
low grade UTUC can be managed endoscopically with
cancer related and overall survival equivalent to that of
nephroureterectomy [18–20]. Because tumor grade is a
significant factor, determining the oncological out-
comes of UTUC in patients treated endoscopically, ure-
teroscopic biopsy is of paramount importance. In our
study, 7/38 patients with presumptive UTUC on CTU
were treated endoscopically. All had biopsy confirming
low grade UTUC less than 1 cm in size. Recurrence oc-
curred in two patients and was amenable for repeat
endoscopic resection. No progression was observed
during a median follow-up time of 17 months. All com-
plications observed in this study were Clavien grade I
or II. Febrile UTI and renal colic were the only post
operative complications, reported in 7 (6 %) patients
and 4 (3 %) patients, respectively. All patients were
successfully treated with antibiotics and analgesics. The
potential adverse oncological effect that may be related
to delayed nephroureterectomy was beyond the scope
of our study, but was addressed in previous publica-
tions. No difference in 5 years metastasis-free, cancer
specific or overall survival was found in patients who
Fig. 1 Diagnostic-Therapeutic Flowchart of patients with filling defect on pre-ureteroscopic CTU
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underwent diagnostic ureteroscopy prior to nephroure-
terectomy compared with patients who did not undergo
ureteroscopy [21–23].
Our study is undoubtedly limited by its retrospective de-
sign and small size. By the reliance on imaging interpret-
ation, CTU technique was not uniform and the results
were subjected to inter observer bias. Despite that, the
PPV of CTU in our study is in accordance with results of
previous studies [12–15]. Another limitation is the rela-
tively short follow up period of patients treated endoscop-
ically. As mention above, high rate of renal preservation
and favorable oncological outcomes were observed in long
term studies when patients were carefully selected. This is
also reflected by the European guidelines on UTUC,
which recognize the option of endoscopic treatment in
low grade low stage UTUC [24].
Conclusions
In this retrospective study, nephroureterectomy was
spared from 42 % of patients with presumptive UTUC,
demonstrated on CTU. In about half of those patients
UTUC has been ruled out and the others were managed
endoscopically. Although false positive seems to occur
mainly in small filling defects on CTU, there is no room
for diagnostic error when nephroureterectomy is being
considered. Hence, our study favors ureteroscopy as a cru-
cial step in confirming UTUC and treatment planning.
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